Alder agrees potential $1 billion deal with BMS for rheumatoid arthritis treatment
This article was originally published in Scrip
Executive Summary
Alder Biopharmaceuticals has signed a licensing agreement with Bristol-Myers Squibb for its lead programme ALD518 that could be worth in excess of $1 billion for the small US biotechnology company.